Aspects of successful drug discovery and development

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 77-89

  Pauwels, Rudi ^a  

^a NONE   (Switzerland)

Author keywords

Chemotherapy; Drug development; HIV; NNRTI; Protease inhibitor

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ADEFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; CYCLAM DERIVATIVE; DAPIVIRINE; DARUNAVIR; DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; IMINOTHIOUREA; ITU R100943; JM 2763; LOVIRIDE; NEVIRAPINE; NUCLEOTIDE COMPETING REVERSE TRANSCRIPTASE INHIBITOR; PREZISTA; PROTEINASE INHIBITOR; PYRIMIDINE DERIVATIVE; R 106168; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; TETRAHYDROIMIDAZOBENZODIAZEPINONE; TIVIRAPINE; TMC 126; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; CELL ASSAY; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LYMPHOBLASTOID CELL; PRIORITY JOURNAL; SHORT SURVEY; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANTI-HIV AGENTS; CELL LINE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 33747140370     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.05.007     Document Type: Short Survey

References (63)

1. Andries K., Azijn H., Thielemans T., Ludovici D., Kukla M., Heeres J., Janssen P., De Corte B., Vingerhoets J., Pauwels R., and de Béthune M.-P. TMC125, a novel next generation nonnucleoside RT inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48 (2004) 4680-4686
2. Aresteh L., Clumeck N., Pozniak A., Jäger H., De Pauw M., Müller H., Peeters M., Hoetelmans R., De Meyer S., Van der Sandt I., Comhaire S., and Van der Geest R. First clinical results on antiretroviral activity, pharmacokinetics, and safety of TMC114, an HIV-1 protease inhibitor, in multiple PI-experienced patients, abstr. 8. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, Mass (2003)
3. Baba M., Pauwels R., Herdewijn P., De Clercq E., Desmyter J., and Vandeputte M. Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem. Biophys. Res. Commun. 142 (1987) 128-134
4. Balzarini J., Holý A., Jindrich J., Naesens L., Snoeck R., Schols D., and De Clercq E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2.6-diaminopurine. Antimicrob. Agents Chemother. 37 (1993) 332-338
5. Balzarini J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr. Topics Med. Chem. 4 (2004) 921-944
6. Berger D., Bellos N., Farthing C., Stryker R., Colson A., Pierone G., Lefebvre E., Cefalone M., Koester A., Van Baelen K., and De Pauw M. TMC114/r in 3-class-experienced patients: 24-week primary safety analysis of the POWER 2 study (TMC114-C202), abstract H-1094. Proceedings of the 45th Annual ICAAC. Washington, DC, USA, December 16-19, 2005 (2005)
7. Brown A.J.L., Simon D., Frost S.D.W., Mathews W.C., Dawson K., Hellman N.S., Daar E.S., Richman D.D., and Little S.J. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J. Infect. Dis. 167 (2003) 683-686
8. Coffin J.M. HIV viral dynamics. AIDS 10 Suppl. 3 (1996) S75-S84
9. Cooper D.A., and Lange J.M.A. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. Lancet 4 (2004) 426-436
10. Das K., Ding J., Hsiou Y., Clark Jr. A.D., Moereels H., Koymans L., Andries K., Pauwels R., Janssen P.A.J., Boyer P.L., Clark P., Smith Jr. R.H., Kroeger Smith M.B., Michejda C.J., Hughes S.H., and Arnold E. Crystal structures of 8-CI and 9-CI TIBO complexed with wild-type HIV-1 RT and 8-CI TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 264 (1996) 1085-1100
11. Das K., Clark Jr. A.D., Lewi P.J., Heeres J., De Jonge M.R., Koymans L.M., Vinkers H.M., Daeyaert F., Ludovici D.W., Kukla M.J., De Corte B., Kavash R.W., Ho C.Y., Ye H., Lichtenstein M.A., Andries K., Pauwels R., De Béthune M.P., Boyer P.L., Clark P., Hughes S.H., Janssen P.A.J., and Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47 10 (2004) 2550-2560
12. De Clercq E., Yamamoto N., Pauwels R., Baba M., Schols D., Nakashima H., Balzarini J., Debyser Z., Murrer B.A., Schwartz D., Thornton D., Bridger G., Fricker S., Henson G., Abrams M., and Picker D. Potent and selective inhibition of HIV-1 and HIV-2 replication by a novel class of bicyclams targeted at viral uncoating. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 5286-5290
13. De Clercq E., Yamamoto N., Pauwels R., Balzarini J., Witvrouw M., De Vreese K., Debyser Z., Rosenwirth B., Peichl P., Datema R., Thornton D., Skerlj R., Gaul F., Padmanabhan S., Bridger G., Henson G., and Abrams M. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38 (1994) 668-674
14. De Clercq E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Disc. 11 (2002) 13-25
15. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present and future. Chem. Biodivers. 1 (2004) 44-64
16. De Clercq E. Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2 (2004) 702-720
17. De Clercq E. Antiviral drug discovery and development: where chemistry meets with biomedicine. Antivir. Res. 67 (2005) 56-75
18. De Clercq E., and Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Disc. 4 (2005) 928-940
19. De Corte B.L. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 48 (2005) 1689-1696
20. De Meyer S., Azijn H., Surleraux D., Jochmans D., Tahri A., Pauwels R., Wigerinck P., and de Béthune M.P. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49 (2005) 2314-2321
21. Dierynck I., Keuleers I.M., De Wit M., Tahri A., Surleraux D.L., Peeters A., and Hertogs K. Poster no. 64. Proceedings of the XIV International HIV Drug Resistance Workshop. Québec City, Canada, June 7-11, 2005 (2005)
22. Domingo E., Mas A., Yuste E., Pariente N., Sierra S., Gutierrez-Riva M., and Menendez-Arias L. Virus population dynamics, fitness variations and the control of viral disease: an update. Prog. Drug 57 (2001) 77-115
23. Fisher A.G., Ensoli B., Looney D., Rose A., Gallo R.C., Saag M.S., et al. Biologically diverse molecular variants within a single HIV-1 isolate. Nature 334 (1988) 444-447
24. Ghosh A., Thompson W., Fitzgerald P., Culberson J., Axel M., McKee S., Huff J., and Anderson P. Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran. J. Med. Chem. 37 (1994) 2506-2508
25. Ghosh A.K., Kincaid J.F., Cho W., Walters D.E., Krishnan K., Hussain K.A., Koo Y., Cho H., Rudall C., Holland L., and Buthod J. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg. Med. Chem. Lett. 8 (1998) 687-690
26. Gruzdev B., Rakhmanova A., Doubovskaya E., Yakovlev A., Peeters M., Rinehart A., de Dier K., Baede-Van Dijk P., Parys W., and van't Klooster G. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naïve HIV-1 infected subjects. AIDS 17 (2003) 2487-2494
27. Hertogs K., de Béthune M.-P., Miller V., Ivens T., Schel P., Van Cauwenberghe A., Van Den Eynde C., Van Gerwen V., Azijn H., Van Houtte M., Peeters F., Staszewski S., Conant M., Bloor S., Larder B., and Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42 (1998) 269-276
28. Hertogs K., Bloor S., Kemp S.D., Van den Eynde C., Alcorn T.M., Pauwels R., Van Houtte M., Staszewski S., Miller V., and Larder B.A. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14 (2000) 1203-1210
29. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., and Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 (1995) 123-126
30. Janssen P.A.J., Lewi P., Arnold E., Daeyaert F., de Jonge M., Heeres J., Koymans L., Vinkers M., Guillemont J., Pasquier E., Kukla M., Ludovici D., Andries K., de Béthune M.-P., Pauwels R., Das K., Clark Jr. A.D., Volovik Y., Hughes S.H., Medaer B., De Knaep F., Bohets H., De Clerck F., Lampo A., Williams P., and Stoffels P. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-benzonitrile (R278474, rilpivirine). J. Med. Chem. 48 (2005) 1901-1909
31. Jochmans D., Kesteleyn B., Marchand B., Götte M., Ivens T., Dehertogh P., Peeters A., Pauwels R., Wigerinck P., and Hertogs K. Identification and biochemical characterization of a new class of HIV inhibitors: nucleotide-competing reverse transcriptase inhibitors, abstract 156. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA, USA, February 22-25, 2005 (2005)
32. Katlama C., Carvalho M.T.M., Cooper D., De Backer K., Lefebvre E., Pedro R., Rombouts K., Stoehr A., Vangeneugden T., and Woehrmann A. TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: week 24 primary efficacy analysis of POWER 1 (TMC114-C213), poster no. WeOaLB0102. Proceedings of the Third IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, July 24-27, 2005 (2005)
33. King N.M., Prabu-Jeyabalan M., Nalivaika E.A., Wigerinck P., de Béthune M.-P., and Schiffer C.A. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78 21 (2004) 12012-12021
34. Kohlstaedt L.A., Wang J., Fiedman J.M., Rice P.A., and Steitz T.A. A crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256 (1992) 1783-1790
35. Koyanagi Y., Harada S., Takahashi M., Uchino F., and Yamamoto N. Selective cytotoxicity of AIDS virus towards HTLV-I transformed cell lines. Int. J. Cancer 36 (1985) 445-451
36. Lee L.M., Karon J.M., Selik R., Neal J.J., and Fleming P.L. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1994-1997. JAMA 285 (2001) 1308-1315
37. Lewi P.J., de Jonge M., Daeyaert F., Koymans L., Vinkers M., Heeres J., Janssen P.A.J., Arnold E., Das K., Clark Jr. A.D., Hughes S.H., Boyer P.L., de Béthune M.-P., Pauwels R., Andries K., Kukla M., Ludovici D., De Corte B., Kavash R., and Ho C. On the detection of multiple-binding modes of ligands to proteins, from biological, structural and modeling data. J. Comput.-Aided Mol. Des. 17 2-4 (2003) 129-134
38. Litller E., and Oberg B. Achievements and challenges in antiviral drug discovery. Antivir. Chem. Chemother. 16 (2005) 155-168
39. Ludovici D.W., Kukla M.J., Grous P.G., Krishnan S., Andries K., de Béthune M.P., Azijn H., Pauwels R., De Clercq E., Arnold E., and Janssen P.A. Evolution of anti-HIV drug candidates. Part 1. From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). Bioorg. Med. Chem. Lett. 11 (2001) 2225-2228
40. Ludovici D.W., Kavash R.W., Kukla M.J., Ho C.Y., Ye H., De Corte B.L., Andries K., de Béthune M.P., Azijn H., Pauwels R., Moereels H.E., Heeres J., Koymans L.M., de Jonge M.R., Van Aken K.J., Daeyaert F.F., Lewi P.J., Das K., Arnold E., and Janssen P.A. Evolution of anti-HIV drug candidates. Part 2. Diaryltriazine (DATA) analogues. Bioorg. Med. Chem. Lett. 11 (2001) 2229-2234
41. Ludovici D.W., De Corte B.L., Kukla M.J., Ye H., Ho C.Y., Lichtenstein M.A., Kavash R.W., Andries K., de Béthune M.P., Azijn H., Pauwels R., Lewi P.J., Heeres J., Koymans L.M., de Jonge M.R., Van Aken K.J., Daeyaert F.F., Das K., Arnold E., and Janssen P.A. Evolution of anti-HIV drug candidates. Part 3. Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 11 (2001) 2235-2239
42. Mellors J.W., Rinaldo Jr. C.R., Gupta P., White R.M., Todd J.A., and Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 (1996) 1167-1170 (Erratum, Science 275 (1997) 14)
43. Mellors J.W., Munoz A., Gigorgi J.V., et al. Plasma viral load and CD4+ cell lymphocytes as prognostic markers of HIV-1 infection. Ann. Int. Med. 126 12 (1997) 946-954
44. Montaner J., Domingo P., Junod P., Lazzarin A., Pozniak A.L., Tsoukas C., Peeters M., Schöller M., Vingerhoets J., and Woodfall B. Safety and tolerability of TMC125 in 3-class-experienced HIV-infected patients: 24-week preliminary analysis of trial. Abstract no. LBPS3/7B. TMC125-C203. Proceedings of the 10th European AIDS Conference. Dublin, Ireland, October 17-20, 2005 (2005)
45. Nadler J., Grossman H.A., Hicks C., Shalit P., Jayaweera D.T., Thompson M., Blick G., Vingerhoets J., Voorspoels E., Peeters M., and Woodfall B. Efficacy and tolerability of TMC125 in HIV patients with NNRTI and PI resistance at 24 weeks: TMC125-C223 poster no. LBPS3/7A. Proceedings of the 10th European AIDS Conference. Dublin, Ireland, October 17-20, 2005 (2005)
46. Overby, S., 2001. Drug companies on speed. COI Magazine, October 15, 2002 Issue. Available on line at: http://www.cio.com/archive/101501/speed.html.
47. Pauwels R., De Clercq E., Desmyter J., Balzarini J., Goubau P., Herdewijn P., Vanderhaeghe H., and Vandeputte M. Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. J. Virol. Meth. 16 (1987) 171-185
48. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., and De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Meth. 20 (1988) 309-321
49. Pauwels R., Balzarini J., Schols D., Baba M., Desmyter J., Rosenberg I., Holy A., and De Clercq E. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 32 (1988) 1025-1030
50. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M.J., Breslin H.J., Raeymaeckers A., Van Gelder J., Woestenborghs R., Heykants J., Schellekens K., Janssen M.A.C., De Clercq E., and Janssen P.A.J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343 (1990) 470-474
51. Pauwels, R., 1993a. Discovery of TIBO, a new family of HIV-1 specific reverse transcriptase inhibitors. In: Adams, J.A, Merluzzi, V.J. (Eds.), Antiviral Drug Discovery, from Concept to Clinic. Birkhäuser Boston, pp. 71-104. ISBN:0-8176-3606-4 (Chapter 4).
52. Pauwels R., Andries K., Debyser Z., Van Daele P., Schols D., Stoffels P., De Vreese K., Woestenborghs R., Vandamme A., Janssen C.G.M., Anné J., Cauwenbergh G., Desmyter J., Heykants J., Janssen M.A.C., De Clercq E., and Janssen P.A.J. Potent and highly selective HIV-1 specific inhibition by a new series of α-anilino-phenylacetamide (α-APA) derivatives targeted at HIV-1 RT. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1711-1715
53. Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr. Opin. Pharmacol. 4 (2004) 437-446
54. Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., and Bozzette S.A. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
55. Sankatsing S.U., Weverling G.J., Peeters M., van't Klooster G., Gruzdev B., Rakhmanova A., Danner S.A., Jurriaans S., Prins J.M., and Lange J.M. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 17 18 (2003) 2623-2627
56. Schols D., Esté J.A., Henson G., and De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antivir. Res. 35 (1997) 147-156
57. Surleraux D.L.N.G., Tahri A., Verschueren W.G., Pille G.M.E., de Kock H.A., Jonckers T.H.M., Peeters A., De Meyer S., Azijn H., Pauwels R., de Béthune M.-P., King N.M., Prabu-Jeyabalan M., Schiffer C.A., and Wigerinck P.B.T.P. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 48 (2005) 1813-1822
58. Surleraux D.L.N.G., de Kock H.A., Verschueren W.G., Pille G.M.E., Maes L.J.R., Peeters A., Vendeville S., De Meyer S., Azijn H., Pauwels R., de Béthune M.P., King N.M., Prabu-Jeyabalan M., Schiffer C.A., and Wigerinck P.B.T.P. Design of HIV-1 protease inhibitors active on multidrug-resitant virus. J. Med. Chem. 48 (2005) 1965-1973
59. Tantillo C., Ding J., Jacobo-Molina A., Nanni R.G., Boyer P.L., Hughes S.H., Pauwels R., Andries K., Janssen P.A.J., and Arnold E. Review article: locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243 (1994) 369-387
60. Vingerhoets J., Van Marck H., Veldeman J., Peeters M., McKenna P., Pauwels R., and de Béthune M.-P. Antiviral activity of TMC125, a potent next-generation NNRTI, against >5000 recombinant clinical isolates exhibiting a wide range of (NNRTI) resistance. Proceedings of the 12th International HIV Drug Resistance Workshop. Cabo San Lucas, Mexico, June 10-14, 2003 (2003) Antivir. Ther. 8 (3) S11
61. Vingerhoets J., Azijn H., Fransen E., De Baere I., Smeulders L., Jochmans D., Andries K., Pauwels R., and de Bethune M.-P. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79 20 (2005) 12773-12782
62. Walker R.T. Antiviral chemotherapy: design or serendipity?. In: De Clercq E. (Ed). Frontiers in Microbiology from Antibiotics to AIDS (1987). 0-89838-959-3 47-61
63. Westby M., Nakayama G.R., Butler S.L., and Blair W.S. Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors. Antivir. Res. 67 (2005) 121-140